Extended Duration Artemether-lumefantrine Treatment for Malaria in Children

Uncomplicated Plasmodium Falciparum Malaria Clinical Trial

— EXALT  

Official title:

Extended Duration Artemether-lumefantrine Treatment for Malaria in Children

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03453840
• Other study ID #: 17-22578
• Secondary ID: 2R01HD068174-06A
• Status: Completed
• Phase: Phase 4
• Start date: February 19, 2018
• Est. completion date: August 31, 2021

Study information

• Verified date: October 2022
• Source: University of California, San Francisco
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This project will determine the pharmacokinetic/pharmacodynamic (PK/PD) of an extended artemether-lumefantrine (AL) dosing regimen in HIV-infected children on efavirenz (EFV)-based antiretroviral therapy (ART) that is designed to improve the PK exposure and treatment efficacy of this artemisinins-based combination therapy (ACT) regimen. Our overarching goal is to inform the best treatment guidelines for young children in Africa. HIV-infected and HIV-uninfected children will be enrolled for intensive PK studies, as well as additional children for population PK studies to enhance association analyses with clinical outcomes.

Description:

This is a prospective multi-site study to evaluate the PK/PD of extended duration AL in HIV-infected children on EFV-based ART and HIV-uninfected children not on ART. AL is the first-line treatment for malaria in Uganda. No change in standard of care treatment will be made for the purposes of this study except for the extension of AL to 5-day dosing. This study will enroll a) HIV-infected children, and b) HIV-uninfected children. All participants may be enrolled through Tororo District Hospital (TDH) or Masafu General Hospital (MGH) in Busia, or other referral centers the area. we will use a design where children will be randomized to either 3-day or 5-day AL and then for subsequent episodes of malaria, should they occur. Conservatively, assuming each enrolled child participates for only a single episode of malaria, up to 60 (30 HIV-infected on 3-day and 30 HIV-infected on 5-day) and 100 (50 HIV-uninfected on 3-day and 50 HIV-uninfected on 5-day) subjects will be enrolled for each of the intensive study groups. Up to 100 (50 HIV-infected on 3-day and 50 HIV-infected on 5-day) and 120 (60 HIV-uninfected on 3-day and 60 HIV-uninfected on 5-day) subjects will be enrolled for each of the population study groups. Comparisons of AL PK exposure will be made among and between a) HIV-infected children with malaria receiving EFV-based ART and b) HIV-uninfected children who are not on ART. Comparisons will be based on an intensive PK design for AL area under the concentration-time curve (AUC) estimations. Population PK study will be combined with intensive PK studies to allow for optimal PK-outcomes assessments.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 305
• Est. completion date: August 31, 2021
• Est. primary completion date: August 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Months to 10 Years

Eligibility

Inclusion Criteria:

1, All participants:

1. Residency within 60 km of the study clinics either at TDH or at MGH

2. Agreement to come to clinic for all follow-up clinical and PK evaluations

3. Provision of informed consent

4. Weight =6 kg

5. Presentation with uncomplicated falciparum malaria as indicated by positive smear for malaria parasites along with clinical evidence of infection (fever or history of fever in the past 24 hours)

6. Willingness to undergo intensive PK sampling and/or population PK sampling during episode(s) of malaria.

2 HIV-infected participants:

1. Confirmed HIV infection (positive rapid HIV test to be confirmed by Western Blot or HIV RNA after enrollment)

2. On stable EFV-based ART for at least 10 days prior to enrollment

3. Age 3 years to 10 years

3 HIV-uninfected participants:

1. Confirmed HIV negative test (negative rapid HIV test to be confirmed by Western Blot or HIV RNA after enrollment)

2. Age 6 months to 10 years

Exclusion Criteria:

1. History of significant comorbidities such as malignancy, active tuberculosis or other World Health Organization (WHO) stage 4 disease

2. Current infection with non-P. falciparum species

3. Receipt of any medications known to affect CYP450 metabolism (except ART) within 14 days of study enrollment (see 4.2.2)

4. Hemoglobin < 7.0 g/dL

5. For the population PK study, prior treatment for malaria within 14 days of enrollment

6. For the intensive PK study, prior treatment for malaria within 28 days of enrollment

7. Signs or evidence of complicated malaria, defined as unarousable coma or any two of the following symptoms: Recent febrile convulsions, altered consciousness, lethargy, unable to drink, unable to stand/sit due to weakness, severe anemia (Hb < 5.0 gm/dL), respiratory distress, jaundice (see Appendix D)

8. History of toxicity to AL

The following medications are disallowed within 3 weeks prior to receiving study drug:

• Carbamazepine

• Clarithromycin

• Erythromycin (oral)

• Ketoconazole

• Phenobarbital

• Phenytoin

• Rifabutin

• Rifampin

• Halofantrine

• Any other medication known to significantly affect CYP450 metabolism.

• Grapefruit juice should be avoided during the study due to its potential effects on CYP3A4.

Related Conditions & MeSH terms

• Malaria
• Malaria, Falciparum
• Uncomplicated Plasmodium Falciparum Malaria

Intervention

Drug:
• Artemether-lumefantrine
Children will receive the dispersible formulation of AL which contains 20 mg artemether, 120 mg of lumefantrine (Coartem® Dispersible). Weight-based dosing will be as below: <15kg, 1tablet; 15-25kg, 2 tablets; 25-35kg, 3 tablets; >=35kg, 4 tablets.

Locations

Country	Name	City	State
Uganda	MGH campus	Busia
Uganda	IDRC- Tororo Research Clinic and Tororo District Hospital	Tororo

Sponsors (4)

Lead Sponsor	Collaborator
University of California, San Francisco	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Infectious Diseases Research Collaboration, Uganda, Yale University

Country where clinical trial is conducted

Uganda, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under the plasma concentration versus time curve (AUC) for all drug analytes	AUC 8hr for artemether and dihydroartemisinin, AUC inf for lumefantrine.	Study day 0-day21
Primary	Recurrent malaria following treatment by day 42 (recrudescence or new infection)	Recurrent malaria determined by microscopy (thick blood smears),loop mediated isothermal amplification (LAMP), or rapid diagnostic test (RDT).	up to study day 42
Secondary	Safety of 5-day vs 3-day AL regimens evaluated via graded toxicity	We will record participants tolerance of AL using the NIH Division of AIDS Adult and Pediatric Toxicity Tables.	study day 0-42
Secondary	Prevalence of gametocytemia following treatment in 3-day vs 5-day AL regimens determined by thick blood smears	At varied time points, blood smears for the determination of parasitemia will be obtained.	study day 0-42
Secondary	Weight-for-age (WFA) associations with PK	weight-for-age is an indicator of nutrition status and decreased weight-for-age reflects the combination of chronic and acute protein-calorie malnutrition.	study day 0
Secondary	Height-for-age (HFA) associations with PK	chronic protein-calorie malnutrition resulting in slow linear growth (decreased height-for-age: HFA; stunting).	study day 0
Secondary	Weight-for-height (WFH) associations with PK	acute protein-calorie malnutrition resulting in weight loss or slow weight gain (decreased weight-for-height: WFH; wasting).	study day 0
Secondary	Diagnostic sensitivity of LAMP, HS-RDT, and microscopy for the detection of recurrent parasitemia	Using Loop-mediated isothermal amplification (LAMP), highly sensitive Rapid Diagnostic Test (HS-RDT), and microscope to diagnose recurrent parasitemia.	study day 0-42
Secondary	Metabolomic measurements in HIV infected vs HIV uninfected children	Small-molecule metabolites, including metabolic intermediates, hormones and other signaling molecules, and secondary metabolites will be measured in plasma and reported as fold-change (e.g. infected vs uninfected). This is an exploratory study. The multiple measurements could be aggregated to fold-change.	study day 0-42
Secondary	Relationship between drug resistance and treatment failure	drug resistance will be accessed by molecular markers. Polymorphic markers will be typed using capillary electrophoresis.	study day 0-42